City Therapeutics, Inc. Common Stock (CTY)

Oct 19, 2026

City Therapeutics Director Ron M Philip Awarded 22,649-Share Stock Option - Kalkine Media

Oct 19, 2026

Oct 19, 2026

ARCH Venture Fund XII Converts Preferred Shares to Common Stock at City Therapeutics IPO - Kalkine Media

Oct 19, 2026

Oct 19, 2026

City Therapeutics closes $230 million upsized IPO By Investing.com - Investing.com South Africa

Oct 19, 2026

Oct 19, 2026

At its IPO close, City Therapeutics (CTY) saw ARCH buy 170,000 shares and convert preferred stock. - Stock Titan

Oct 19, 2026

Oct 19, 2026

At the IPO closing, ARCH bought 170,000 City Therapeutics (CTY) shares at $18 each. - Stock Titan

Oct 19, 2026

Oct 19, 2026

IPO conversion gives City Therapeutics (CTY) director John Maraganore 610,759 common shares. - Stock Titan

Oct 19, 2026

Oct 19, 2026

Director receives 22,649 stock options with an $18 exercise price at City Therapeutics (CTY). - Stock Titan

Oct 19, 2026

Oct 19, 2026

IPO closing fully vests 77,979 CEO options at City Therapeutics (CTY). - Stock Titan

Oct 19, 2026

Oct 19, 2026

A director receives 22,649 City Therapeutics (CTY) options with an $18 exercise price. - Stock Titan

Oct 19, 2026

Oct 19, 2026

Barry E. Greene acquires an option on 22,649 City Therapeutics (CTY) shares with an $18 exercise price. - Stock Titan

Oct 19, 2026

Oct 19, 2026

City Therapeutics closes $230 million upsized IPO By Investing.com - Investing.com Canada

Oct 19, 2026

Oct 19, 2026

A company developing medicines that silence genes brought in about $230 million before costs. - Stock Titan

Oct 19, 2026

Oct 19, 2026

City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance Singapore

Oct 19, 2026

Oct 19, 2026

City Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - GlobeNewswire

Oct 19, 2026

Oct 18, 2026

City Therapeutics, Inc. (CTY) Company Information - Simply Wall Street

Oct 18, 2026

Oct 17, 2026

City Therapeutics (CTY) director Barry E. Greene holds an option to buy 59,878 shares at $0.92 each. - Stock Titan

Oct 17, 2026

Oct 17, 2026

A director’s City Therapeutics (CTY) holdings include an option for 135,611 shares at $5.36. - Stock Titan

Oct 17, 2026

Oct 17, 2026

Director Ron M. Philip holds a $0.92 option on 59,878 City Therapeutics (CTY) shares - Stock Titan

Oct 17, 2026

Oct 17, 2026

Medical chief holds options with $1.84 and $5.36 exercise prices at City Therapeutics (CTY). - Stock Titan

Oct 17, 2026

Oct 17, 2026

CEO holds 1.06M shares in City Therapeutics (CTY), plus options priced at $0.92 and $5.36. - Stock Titan

Oct 17, 2026

Oct 17, 2026

Holdings in City Therapeutics (CTY) include 2.72M common shares and convertible preferred stock. - Stock Titan

Oct 17, 2026

Oct 17, 2026

Director Sara Nochur holds an option on 59,878 City Therapeutics (CTY) shares at a $0.92 exercise price. - Stock Titan

Oct 17, 2026

Oct 15, 2026

City Therapeutics prices IPO at $18 per share, raising $200M - Investing.com

Oct 15, 2026

Oct 15, 2026

A stock sale is expected to bring City Therapeutics about $200 million. - Stock Titan

Oct 15, 2026

Oct 15, 2026

City Therapeutics (CTY) COO holds 534,511 shares plus options exercisable at $0.92 and $5.36. - Stock Titan

Oct 15, 2026